Intraventricular administration of amikacin for complicated Gram-negative meningitis and ventriculitis.
Four pediatric neurosurgical patients with Gram-negative meningitis and ventriculitis were treated with parenteral and intraventricular amikacin, a new aminoglycoside. The organisms infecting these patients were resistant to multiple antimicrobial drugs but were sensitive to amikacin. Treatment was continued for 14 days after cerebrospinal fluid cultures became negative. All four patients were cured and have demonstrated no nephrotoxicity, ototoxicity, or evidence of persistent infection on follow-up examination.
D000151:Acinetobacter Infections / Q000188:drug therapy*; D000583:Amikacin / Q000008:administration & dosage*; D002675:Child, Preschool; D004660:Encephalitis / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007276:Injections, Intraventricular; D007612:Kanamycin / Q000031:analogs & derivatives*; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology; D012706:Serratia marcescens
D007612:Kanamycin; D000583:Amikacin